Group 1 - The core point of the article is that Fuhong Hanlin's innovative PD-1 inhibitor, H drug Surulitinib, has been officially included by the NMPA as a breakthrough therapy for gastric cancer, which could significantly improve patient survival and quality of life [1] - Fuhong Hanlin's stock rose over 6% in the afternoon trading session, with a current price of 66.95 HKD and a trading volume of 63.1355 million HKD [1] - The phase III clinical study for the H drug has met its primary endpoint, indicating its potential to replace postoperative adjuvant chemotherapy in the perioperative treatment of gastric cancer [1] Group 2 - As of the announcement date, there are no approved targeted PD-1 monoclonal antibody drugs for neoadjuvant/adjuvant treatment of gastric cancer globally [1] - According to IQVIA MIDAS data, the global sales of targeted PD-1 monoclonal antibody drugs are projected to reach approximately 45.704 billion USD in 2024 [1]
港股异动 | 复宏汉霖(02696)午后涨超6% 斯鲁利单抗近期获NMPA纳入突破性治疗品种